Eef1A1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
eEF1A1 is a eukaryotic translation elongation factor involved in protein synthesis. It plays a critical role in delivering aminoacyl-tRNAs to the ribosome during the elongation phase of translation. Mutations or dysregulation of these translation factors are associated with various diseases including neurodegeneration, cancer, and ribosomopathies.
.infobox .infobox-protein
{
float: right;
width: 300px;
padding: 10px;
background: #f8f9fa;
border: 1px solid #ddd;
border-radius: 4px;
margin: 10px;
}
.infobox .infobox-protein th
{
background: #28a745;
color: white;
padding: 8px;
}
.infobox .infobox-protein td
{
padding: 6px;
}
eEF1A1 has a classic GTP-binding protein fold with domain I binding GTP/GDP and domain II-III binding tRNA. It exists in two isoforms (eEF1A1 and eEF1A2) with tissue-specific expression.
eEF1A1 is the alpha subunit of elongation factor-1, responsible for delivering aminoacyl-tRNAs to the ribosome. It is one of the most abundant cellular proteins. Beyond translation, it is involved in cytoskeletal organization, signal transduction, and apoptosis.
Dysregulation has been linked to neurodegenerative diseases including ALS and PD. eEF1A2 is specifically expressed in neurons and muscle.
No specific inhibitors. The protein is being studied for its role in amyloid-beta toxicity in AD.
The study of Eef1A1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.